NCT01620242View on ClinicalTrials.gov

A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

May 27, 2014

Conditions
Recurrent Head and Neck CancerMetastatic Head and Neck Cancer
Interventions
DRUG

Cabazitaxel

25 mg/m2 every 3 weeks by IV administration

Trial Locations (5)

59020

Centre Oscar Lambret, Lille

69008

Centre Léon Berard, Lyon

75231

Institut Curie, Paris

94805

Institut Gustave Roussy, Villejuif

06189

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

UNICANCER

OTHER

NCT01620242 - A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes | Biotech Hunter | Biotech Hunter